Frontlight ResearchEarly access
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Key facts
- Who runs it
- Research Center of Neurology, Russia
- Where
- Russia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 4
- People taking part
- 30 people enrolled
- Started
- 1 Apr 2026
- Expected to end
- 25 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Mexidol sequential therapy
- Record updated
- 6 November 2026
Who can take part
- Age
- 50 years to 74 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (6)Hide the full registry criteria
Who can take part
- cerebrovascular disease (I67.8) and/or cerebral atherosclerosis (I67.2)
- metabolic disorders (diabetes and/or BMI 27 or higher) for Group1
- no metabolic disorders - for Group 2
Who cannot take part
- history of neoplasia
- acute stroke/myocardial infarction
- decompensated somatic pathology
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
We aim to elucidate the metabolic and neuroactive properties of sequential Mexidol therapy in patients with and without cerebrometabolic disorders using blood biomarkers, anthropometry and brain functional MRI (task- and rest).
The 2 groups in the trial
- Cerebrovascular disease without metabolic disordersExisting treatment, for comparison
Treatment: Mexidol sequential therapy
- Cerebrovascular disease with metabolic disorders (obesity and/or DM2)Treatment being tested
Treatment: Mexidol sequential therapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 6 November 2026